RLT Angels

Scaling care for cancer patients with radiotheranostics

Radiotheranostics represents an innovative approach, combining diagnostic imaging (RLI) and targeted therapeutics (RLT) using radionuclides to identify and fight cancer, offering precise treatment that preserves healthy tissues.1-4

RLT Angels is a global non-profit association dedicated to maximizing patient access to radiotheranostics, systematically expanding health system ability to deliver radioligand imaging and radioligand therapies, and improving the experience and outcomes for patients, globally.

Sources
  • (1) Bugani V, Battistelli L, Sansovini M, et al. Radioligand therapies in cancer: mapping the educational landscape in Europe [published online ahead of print, 2023 Apr 14]. Eur J Nucl Med Mol Imaging. 2023;1-7.
  • (2) Uijen MJM, Derks YHW, Merkx RIJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48(13):4350-4368.
  • (3) Burkett BJ, Bartlett DJ, McGarrah PW, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023;5(4):e220157.
  • (4) Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges [published correction appears in Nat Rev Drug Discov. 2020 Sep 7]. Nat Rev Drug Discov. 2020;19(9):589-608.

Connect

Legal

Press releases

All rights reserved © 2025 RLT Angels